Monday , October 18 2021

▷ Californian research team publishes promising results for …



[ad_1]

Santa Clara, California (PRNewswire / -) – A team of researchers from Dr. Ing Rath Research Institute in California has developed a cancer vaccine that reduces tumor growth. This peptide-based vaccine targets specific enzymes called metalloproteinases (MMPs), which are responsible for tumor growth, metastatic formation, and blood vessels in tumors (angiogenesis). Dr. Rath's research team showed that tested mice vaccinated with peptides containing MMP-2 and MMP-9 specific sequences and subsequently infected with melanoma cancer cells had an average tumor reduction of approximately 76% compared to unvaccinated animals of the control group. Remarkably, some vaccinated animals have not developed cancer.

The study was published in October 2018 in the Online Journal of Cellular Medicine and Natural Health.

Cancer is still the biggest epidemic in the world. The disease causes over 7 million deaths each year. This new approach to therapy has the potential to significantly change these statistics. Compared with monoclonal antibodies (MAB) or biosimilar molecules recently developed as anti-cancer agents, the anti-MMP vaccine approach promises to be much more effective and accessible in the global fight against the disease. While Mabs / biosimilars target a certain type of cancer, the anti-MMP vaccine can combat all types of cancer. Another advantage is that, unlike Mabs / Biosimilar, where an injection should usually be performed once or twice a month, the anti-MMP vaccine should be injected once and vaccination after several years would be necessary.

The anti-MMP vaccine, if successfully completed, could be offered to patients in national or international medical institutions at a reasonable cost.

To make this affordable technology affordable for most patients and nations around the world, Dr. Rath Research Institute has called for protection in many countries. The Institute seeks public and governmental research institutions and other nonprofit institutions to develop this promising technology with them in order to successfully treat, prevent, and eventually eliminate cancer.

Source: https://www.jcmnh.org/peptide-vaccines-directed-against-human-metalloproteinases-mmps-with-anti-tumor-efficacy-in-vitro-and-in-vivo/

U.S. Patents no. 8003110 and 8067009

Photos – https://mma.prnewswire.com/media/780637/Dr_Rath_Cancer_Vaccine.jpg

Contact press:

Dr. Alexandra Niedzwiecki
CEO-
Dr. Rath Research Institute
E-mail: [email protected]

Original Content by: Dr. med. Rath Research Institute, transmitted through actell news

[ad_2]
Source link